fatnews.com Home page  >  Article | Previous article | Next article

SEARCH

QUICKLINKS AND VIEW OPITONS

  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • Follow @fatnews

    Depression-related events more common in those given 15 mg phentermine + 92 mg Topamax: 7.3% vs 3.8%


    Posted by .(JavaScript must be enabled to view this email address)
    Tuesday, April 26, 2011 2:33 pm Email this article
    "Depression-related adverse events (excluding sleep disorders)" occurred in 7.3 percent of patients given 15 mg of phentermine plus 92 mg of Topamax (topiramate) versus 3.8 percent in those given 7.5 mg of phentermine plus 46 mg of Topamax (topiramate) versus 3.8 percent in those given a placeboaccording to a new study from Duke University in Durham, North Carolina, USA.

    It took an average of approximately one-month for these symptoms to occur. Subjects

    Subjects: 2487 overweight and obese patients

    The study wad done at 93 centers in the US and involved 2487 overweight and obese patients who were 18- to 70-years-old, with an average age of 51.

    Seventy percent (70%) of subjects were women.

     

    Body Weight

    Average body weight: 226 lbs; BMI 36-37

    The average body weight of the subjects was 226 pounds.

    The average body mass index (BMI) was 36-37.

     

    Other articles about Phentermine plus Topamax

    Other articles about Phentermine plus Topamax

    Other articles about Phentermine plus Topamax are posted here:

    Robert Skversky, MD on Dr. Oz talking about Phentermine plus Topamax for weight loss, Part 1

    Robert Skversky, MD on Dr. Oz talking about Phentermine plus Topamax for weight loss, Part 2

    Robert Skversky, MD on Dr. Oz talking about Phentermine plus Topamax for weight loss, Part 3

    Robert Skversky, MD on Dr. Oz talking about Phentermine plus Topamax for weight loss, Part 4

    Robert Skversky, MD on Dr. Oz talking about Phentermine plus Topamax for weight loss, Part 5

    Topamax (topiramate) caused average weight gain of 5.3 lbs in six months in migraine suffers

    Woman loses 40 lbs on Topamax with Robert Skversky, MD

    Woman loses 115 lbs on phentermine, Topamax and Lexapro with Robert Skversky, MD

    How I use Topamax for weight loss by Robert Skversky, MD

    Qnexa (phentermine plus Topamax) causes woman to lose 55 lbs, man 73 lbs

    High-dose Qnexa: 15 mg Phentermine plus 92 mg Topamax causes weight loss of 10.4% vs 1.8% w/placebo

    Mid-dose Qnexa: 7.5 mg Phentermine plus 46 mg Topamax causes weight loss of 8.4% vs 1.8% w/placebo

    High-dose Qnexa: 15 mg Phentermine plus 92 mg Topamax causes weight loss of 11% vs 1.6% w/placebo

    Low-dose Qnexa: 3.75 mg Phentermine plus 23 mg Topamax causes weight loss of 5.1% vs 1.6% w/placebo

    Qnexa (Phentermine/Topamax) side effects dry mouth, tingling, constipation, altered taste, insomnia

    Topamax (topiramate) used by 50% of weight loss doctors surveyed

    Qnexa (Phentermine/Topamax) side effects dry mouth, tingling, constipation, altered taste, insomnia

    Topamax and Zonegran can increase the risk of suicidal thoughts and behaviors according to the FDA

    Topamax caused weight loss of 15.8 lbs in 59% of patients who gained weight on psychotropic drugs

    43-year-old man loses 50 lbs in 4 months on phentermine plus Topamax (topiramate) - update

    43-year-old man loses 44 lbs in 3 months on phentermine plus Topamax (topiramate)

    Topamax caused psychosis in brother & sister; 75 mg twice a day in one, 25 mg twice a day the other

    Type 2 Diabetics given Topamax lost 13.2 lbs vs 5.5 lbs for those given a placebo

     

    Other articles about Phentermine plus Topamax Posted Later

    Other articles about Phentermine plus Topamax posted after this article

    Other articles posted after this article can be found here.

    REFERENCE

    Gadde K, Allison D, Ryan D, Peterson C, Troupin B, Schwiers M, Day W. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (conquer): A randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Apr 16, 377(9774):1341-52.

    AUTHOR’S CONTACT INFORMATION

    Dr Kishore M Gadde
    Obesity Clinical Trials Programme
    Box 3292
    Duke University Medical Center
    Durham, NC 27710, USA
    .(JavaScript must be enabled to view this email address)

    Articles on the same subject can be found here:


    COMMENTS

    Please feel free to share your comments about this article.


    Name:

    Email:

    Comments:

    Please enter the word you see in the image below:


    Remember my personal information

    Notify me of follow-up comments?



    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.